Next Article in Journal
Efficacy of Neoadjuvant Targeted Therapy for Borderline Resectable III B-D or IV Stage BRAF V600 Mutation-Positive Melanoma
Next Article in Special Issue
Association of Rare Immune-Related Adverse Events to Survival in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Single-Center Cohort Study
Previous Article in Journal
BRCA1 and Metastasis: Outcome of Defective DNA Repair
Previous Article in Special Issue
Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis
 
 
Review

Article Versions Notes

Cancers 2022, 14(1), 109; https://doi.org/10.3390/cancers14010109
Action Date Notes Link
article xml file uploaded 27 December 2021 11:28 CET Original file -
article xml uploaded. 27 December 2021 11:28 CET Update https://www.mdpi.com/2072-6694/14/1/109/xml
article pdf uploaded. 27 December 2021 11:28 CET Version of Record https://www.mdpi.com/2072-6694/14/1/109/pdf
article html file updated 27 December 2021 11:29 CET Original file -
article html file updated 31 July 2022 00:39 CEST Update https://www.mdpi.com/2072-6694/14/1/109/html
Back to TopTop